For biotechnology companies, there can be a few positive news – a major result of clinical trials or the discovery of new drugs, for example – is the difference between the main gathering based on a path towards continuous profitability and stagnation that can eventually lead to the disappearance of the company.
This highly dangerous industry is home to some of the most influential drug makers in the world, but it is also full of a relative unknown that may see or not witness a big boom.
Three companies in the field of biotechnology may emerge for investors to obtain prominent price stimuli, either recently achieved or probably on the horizon. According to analysts, each of these companies already has positive returns from year to date-despite their different degrees-and a wide area for treating the upward trend.
The name of the medical device is hidden in the FDA news, where analysts remain optimistic
Boston Scientific today
Boston Scientific
As of 03:59 pm
- 52 weeks
- 78.90 dollars
▼
108.94 dollars
- P/E ratio.
- 62.61
- The target price
- 117.50 dollars
Boston Scientific Company Nyse: bsx It makes medical devices to diagnose and treat intestinal and pulmonary conditions, among other things. The widely common heart devices in the company were the subject of safety alerts from the FDA (FDA), which led to a slight decrease in the share price, although BSX shares have since regained most of this decrease.
This may be because the company suggested that the risk of its guard device, used to reduce the risk of stroke, is not related to the system design itself or its manufacture, but rather with other factors such as the level of anesthesia used during transplantation.
Since the company is traveling in this challenge, it also has positive news to its wandering. Which are FDA recently agreed The expanded use of the Farapulse pelvis system to treat some atrial fibrillation, a condition that affects approximately 60 million people.
Regarding financial data, Boston is strong-organic sales increased by 17 % on an annual basis (YOY) for the last quarter, with 28 % for Watchman specifically, and the company beat analysts’ predictions at both the upper and basic lower. with 24 out of 26 analysts looking at BSX as a purchaseAnd the bullish capabilities of more than 10 %, investors may find these arrows convincing, although it is expensive.
The dominant leather product sees new approvals, as well as developing pipelines
Arcutis Biological Treatment today
Arcutis Biotere
As of 04:00 pm
- 52 weeks
- 8.03 dollars
▼
$ 17.75
- The target price
- 19.80 dollars
Arcutis Biotherapics Inc. Nasdaq: arqtt It is a biomedic company that focuses on potential drug treatments for skin diseases. One of its basic products is Zoryve, a topical treatment for plaque psoriasis and eczema. The success of this treatment has helped increase the growth of 164 % on products sales to the last quarter, and the company should help achieve a free cash flow by next year.
Although Arcutis faces intensive competition, the dominance of Zoryve-represents nearly half of all the recipes of non-steroidal psoriasis-besides the important important developments of pipelines, providing stability. The Food and Drug Administration (FDA) recently agreed to the company’s Zoryve foam for psoriasis on the scalp and Pody Plaque, providing access to a new set of customers, and the company expects additional decisions from the organizers later in the year.
Arcutis also has a strong assortment of medications in development, including a candidate for atopic dermatitis, and new studies on candidates for vitiligo and pond inflammation.
Arcutis does not have great attention to the analyst like Boston Scientific, but six out of seven analysts assessed Arqt A Buell significantly, the company may have 24 % of the upscale capabilities, although climbing is already about 10 % YTD.
The success of the main Demodex treatment and a promising pipeline
Tarsus Pharmaceuticals today
Tarsus Pharmaceuticals
As of 04:00 pm
- 52 weeks
- $ 25.53
▼
$ 57.90
- The target price
- 66.67 dollars
Another biopharma company, Tarsus Pharmaceuticals Inc. Nasdak: Qatar It focuses on eye care. Although the company has deployed wider losses of the arrow per share of 48 cents in the second quarter, it also reported that net strong sales of about $ 103 million, thanks to XDEMVY sales, treatment for Demodex ice inflammation, and its successful campaign for the consumer.
Investors may be interested in following the suspended study in the second phase of the company for TP-04, a candidate for the treatment of pink in-kind, which seems promising. He led this and other medications in the Tarsus pipeline Six out of seven analysts to evaluate the company purchase.
Tars shares increased by about 4 % YTD, but with more than 16 % in the potential of the upward trend, the company may have a large space for a continuous gathering.
Before you think about Boston, you will want to hear this.
Marketbeat follows the best research analyst at Wall Street, the best performance in Wall Street and the stocks they recommend to their customers on a daily basis. Marketbeat has selected the five shares whose senior analysts whispered quietly to its customers to buy now before holding the broader market … and was not Bostigific in the list.
While Boston currently has a purchase classification between analysts, higher -rated analysts believe that these five stocks buy better.
Show the five stocks here
Enter your email address and we will send you the Marketbeat menu that includes seven shares and why their long -term expectations are very promising.
